[
  {
    "ts": "2025-11-20T04:02:47+00:00",
    "headline": "3 Reasons HOLX is Risky and 1 Stock to Buy Instead",
    "summary": "Over the past six months, Hologic has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $74.17, representing a healthy 31.3% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finance.yahoo.com/news/3-reasons-holx-risky-1-040247006.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "cd664ad5-cdd9-3ad3-b93b-0bee6f83f182",
      "content": {
        "id": "cd664ad5-cdd9-3ad3-b93b-0bee6f83f182",
        "contentType": "STORY",
        "title": "3 Reasons HOLX is Risky and 1 Stock to Buy Instead",
        "description": "",
        "summary": "Over the past six months, Hologic has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $74.17, representing a healthy 31.3% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
        "pubDate": "2025-11-20T04:02:47Z",
        "displayTime": "2025-11-20T04:02:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/79dab4cf82f2f6c9517c9ca1f86b9ec6",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "HOLX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IA27MUxQWSS5U_aghxi8Pw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/79dab4cf82f2f6c9517c9ca1f86b9ec6.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AP1CY6lUwaLn8kK9D5f25Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/79dab4cf82f2f6c9517c9ca1f86b9ec6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-holx-risky-1-040247006.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-holx-risky-1-040247006.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:31:25+00:00",
    "headline": "Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences",
    "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
    "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
      "content": {
        "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
        "contentType": "STORY",
        "title": "Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences",
        "description": "",
        "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
        "pubDate": "2025-11-20T14:31:25Z",
        "displayTime": "2025-11-20T14:31:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "TPG"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "RNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:31:25+00:00",
    "headline": "US healthcare group Abbott bets on cancer screening technology in $23bn deal",
    "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
    "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
      "content": {
        "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
        "contentType": "STORY",
        "title": "US healthcare group Abbott bets on cancer screening technology in $23bn deal",
        "description": "",
        "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
        "pubDate": "2025-11-20T14:31:25Z",
        "displayTime": "2025-11-20T14:31:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "TPG"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "RNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T22:12:34+00:00",
    "headline": "Why the Narrative Around Hologic Is Changing After the Blackstone and TPG Acquisition News",
    "summary": "Hologic’s consensus analyst price target has nudged upward, rising from $75.08 to $76.17 per share. This change comes amid increased attention following news of a proposed acquisition. The slight boost reflects a mix of optimism regarding the deal's valuation and ongoing uncertainty about the company’s growth prospects. Read on to find out how these evolving dynamics may influence Hologic’s stock narrative and what steps you can take to stay informed as the story develops. Analyst Price...",
    "url": "https://finance.yahoo.com/news/why-narrative-around-hologic-changing-221234047.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "79643193-1a9c-3a19-9b1a-b6ab4f029b98",
      "content": {
        "id": "79643193-1a9c-3a19-9b1a-b6ab4f029b98",
        "contentType": "STORY",
        "title": "Why the Narrative Around Hologic Is Changing After the Blackstone and TPG Acquisition News",
        "description": "",
        "summary": "Hologic’s consensus analyst price target has nudged upward, rising from $75.08 to $76.17 per share. This change comes amid increased attention following news of a proposed acquisition. The slight boost reflects a mix of optimism regarding the deal's valuation and ongoing uncertainty about the company’s growth prospects. Read on to find out how these evolving dynamics may influence Hologic’s stock narrative and what steps you can take to stay informed as the story develops. Analyst Price...",
        "pubDate": "2025-11-20T22:12:34Z",
        "displayTime": "2025-11-20T22:12:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qYSQ6AG4c18KIEG8bfQS1g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mH32bjf22B8VXoaGCZudBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-hologic-changing-221234047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-hologic-changing-221234047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "TPG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]